Effect of Intranasal Midazolam Versus Ketamine Midazolam Combination as a Premedication on the Occurrence of Postoperative Respiratory Adverse Events

Kasr El Aini Hospital200 enrolled

Overview

The aim of this study is to investigate the effect of addition of intranasal ketamine to midazolam compared to midazolam alone as a premedication on the occurrence of PRAEs

Perioperative respiratory adverse events (PRAEs) are the most common complication during pediatric anesthesia furthermore, most children presenting for AT have sleep-disordered breathing and obstructive sleep apnea syndrome (OSAS) caused by tonsillar hypertrophy which could aggravate the PRAEs specially with the use of the conventional sedatives as a premedication. A recent randomized controlled trial has shown that more than 50% of children premedicated with midazolam had experienced PRAEs . Midazolam and ketamine are commonly used as preoperative sedative drugs for pediatric populations. Ketamine is a safe and widely used sedative and analgesic in the pediatric emergency department (ED) with less profound effects on the upper airway and respiratory muscles. Intranasal ketamine administration is well tolerated and without serious adverse effects. The addition of ketamine to midazolam as a preoperative sedation to reduce the occurrence of PRAEs was not investigated before in children undergoing AT. The authors hypothesize that combination of ketamine to midazolam could offer optimum sedation condition while reducing the occurrence of PRAEs in children undergoing AT.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

200

Conditions

Tonsillectomy Adenoidectomy Drug-Related Side Effects and Adverse Reaction

Interventions

The midazolam groupDRUG

The midazolam group will receive intranasal midazolam (0.1 mg/kg)

The midazolam ketamine groupDRUG

the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)

Eligibility

Sex: ALLMin age: 3 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children both sexes male and female. * Age from 3 to 12 years old. * ASA grade I, II. * undergoing elective AT procedures. Exclusion Criteria: * Congenital heart diseases (cyanotic and a cyanotic). * Congenital syndromes affecting airway anatomy such as Pierre-Robin syndrome and Down syndrome. * Severe lung diseases affecting either lung tissue such as pulmonary cystic fibrosis and idiopathic pulmonary fibrosis or affecting lung circulation such as pulmonary hypertension with marked limitation of Physical activity or inability to carry out any physical activity according to NHYA classification. * Recent upper respiratory tract infection (less than two weeks). * Neuromuscular diseases including cerebral palsy and epilepsy.

Locations (1)

Cairo university hospitals, kasralainy

Cairo, Egypt

Outcomes

Primary Outcomes

The incidence of any perioperative respiratory adverse events (PRAEs)

the incidence of any PRAEs (Perioperative respiratory adverse events (PRAEs) which are manifested as minor (oxygen desaturation (SaO2 less than 95% for 10 seconds) or coughing) and major as (bronchospasm, laryngospasm, airway obstruction, stridor or hypoxia (oxygen desaturation less than 90%)) among midazolam versus midazolam ketamine groups.

Time frame: 8 hours

Secondary Outcomes

Postoperative pain score

• Postoperative pain score using (Wong-Baker Pain Scale)

Time frame: 8 hours

Sedation success rate

• Sedation success rate (score of 3 or 4 is considered successful sedation) using Funk score

Time frame: 8 hours

Postoperative emergence delirium

• Postoperative emergence delirium, a total Postoperative emergence delirium PAED score≥ 10 will be considered indicative of the presence of ED using (PAED scale

Time frame: 8 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.